mean concentration of 0.63 mmol/L, is a powerful acute phase reactant as it changes dramatically during vascular injury and inflammatory processes5. Albumin acts as a buffering agent for endogenous or exogenous toxic molecules due to its various ligands binding ability4,5. The biochemical mechanisms modifying the amino-terminal region of albumin during ischemia are unclear, but reperfusion afte...

BACKGROUND The increasingly high incidence of ischemic stroke caused by thrombosis of the arterial vessels is one of the major factors that threaten people's health and lives in the world. The present treatments for thrombosis are still unsatisfactory. Herbal preparations have been used since ancient times for the treatment of several diseases. The aim of this study was to investigate whether h...

BACKGROUND Although thrombolytic therapy has shown substantial benefits in neural outcomes, concerns remain regarding the association between thrombolytic therapy and possible increased mortality. OBJECTIVE To determine the mortality risk of certain thrombolytic agents that are a treatment option for acute ischemic stroke. DATA SOURCES, EXTRACTION, AND SYNTHESIS Studies were identified usin...

It has been observed that ticlopidine and clopidogrel show, apart from their delayed antiplatelet properties, an immediate and transient thrombolytic action related to the ability of these thienopyridines to stimulate the secretory function of vascular endothelium. With the objective to construct new molecules with identical thrombolytic potency but at a higher level, we carried out different s...

OBJECTIVES To compare a system of prehospital thrombolytic therapy, delivered by paramedics under medical guidance, with in-hospital thrombolytic therapy in meeting National Service Framework (NSF) targets for treatment of acute myocardial infarction at a District General Hospital setting in England. DESIGN Retrospective observational case-control study comparing patients with suspected acute...

In patients with massive pulmonary embolism threatened by haemodynamic instability, thrombolytic treatment is recommended. But when it fails, therapeutic options remain limited and are mainly guided by local expertise. In the current case, we report a potential treatment modality for this situation. A 60-year-old male patient collapsed several times at home. He had a history of a curative left ...

The results of the ER-TIMI (Thrombolysis in Myocardial Infarction) 19 trial (1) provide yet another building block in the case for prehospital administration of thrombolytic agents to patients presenting with acute ST-segment elevation myocardial infarction (MI). These results reflect as accurately as possible the contemporary impact on time to administration (32-min decrease), and they come at...

The reperfusion era has dramatically and irrevocably transformed the management of ST-segment elevation myocardial infarction (STEMI). For the patient treated with fibrinolysis as the initial reperfusion strategy, subsequent options which are the subject of some controversy and the focus of this review are (i) facilitated percutaneous coronary intervention (PCI); (ii) pharmacoinvasive approach;...

AIM Thrombolytic therapy induces faster clot dissolution than anticoagulation in patients with acute pulmonary embolism (PE) but is associated with an increased risk of haemorrhage. We reviewed the risks and benefits of thrombolytic therapy in the management of patients with acute PE. METHODS AND RESULTS We systematically reviewed randomized controlled studies comparing systemic thrombolytic ...

BACKGROUND The efficacy of thrombolytic therapy for acute ischemic stroke remains controversial in emergency medicine and has not been fully endorsed by either the American College of Emergency Physicians or the American Academy of emergency medicine. A growing recognition exists of the influence of pharmaceutical sponsorship on the reported findings of published clinical trials. Sponsorship bi...